Jefferies analyst Roger Song reiterated a Buy rating and $28.00 price target on WAVE Life Sciences (NASDAQ: WVE).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

RBC on WAVE Life Sciences (WVE): 't we continue to see a molecule that is pharmacologically active and remain optimistic'March 27, 2026 5:04 AM WAVE Life Sciences (WVE) PT Lowered to $39 at Clear Street, 'we think ‘007 should find its optimal patient population'March 26, 2026 4:21 PM B.Riley on WAVE Life Sciences (WVE): 'a ~60% intraday selloff that, in our view, is significantly overdone'March 26, 2026 12:23 PM Leerink Partners on WAVE Life Sciences (WVE) after obesity data disappoints: selloff 'very overdone'March 26, 2026 9:00 AM Jones Trading on WAVE Life Sciences (WVE) GLP-1: 'we still see the chance for utility in elderly or patients with metabolic disease'March 26, 2026 8:55 AM Leerink on WAVE Life Sciences (WVE) Amid 52pct Collapse: 'The stock's reaction premarket... is very overdone in our opinion'March 26, 2026 8:52 AM Oppenheimer on WAVE Life Sciences (WVE): 'we would be buyers any weakness'March 26, 2026 8:20 AM Form 8-K Wave Life Sciences Ltd. For: Mar 26March 26, 2026 7:41 AM Wave Life Sciences reports phase 1 obesity drug resultsMarch 26, 2026 7:30 AM Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at SixMarch 26, 2026 7:30 AM Jefferies on WAVE Life Sciences (WVE): 'We see reasonable bars for WVE's RNA editor to approach target protein levels'March 25, 2026 11:56 AM WAVE Life Sciences (WVE) PT Raised to $27 at MizuhoMarch 24, 2026 4:56 PM